Pain in Parkinson disease: mechanistic substrates, main classification systems, and how to make sense out of them

Pain 2023 Nov 1;164(11):2425-2434. doi: 10.1097/j.pain.0000000000002968. Epub 2023 Jun 6. Daniel Ciampi de Andrade, Veit Mylius, Santiago Perez-Lloret, Rubens G Cury, Kirsty Bannister, Xavier Moisset, Gabriel Taricani Kubota, Nanna B Finnerup, Didier Bouhassira, Kallol Ray Chaudhuri, Thomas Graven-Nielsen, Rolf-Detlef Treede Abstract Parkinson disease (PD) affects up to 2% of the general

Real-life study of the use of oto-acoustic emissions in the diagnosis of intracranial hypotension

Revue Neurologique 2023 Oct 10:S0035-3787(23)01046-9.doi: 10.1016/j.neurol.2023.07.014. Online ahead of print. J Pascaud, S Redon, M Elzière, A Donnet Abstract Background: The diagnosis of spontaneous or post-traumatic intracranial hypotension (IH) mainly relies on clinical features and neuro-imaging. However, the results of brain and spine

Acid-sensing ion channel 3 mediates pain hypersensitivity associated with high-fat diet consumption in mice

Pain 2023 Sep 21.doi: 10.1097/j.pain.0000000000003030. Online ahead of print. Ahmed Negm, Katharina Stobbe, Selma Ben Fradj, Clara Sanchez, Arnaud Landra-Willm, Margaux Richter, Lucile Fleuriot, Delphine Debayle, Emmanuel Deval, Eric Lingueglia, Carole Rovere, Jacques Noel   Abstract Lipid-rich diet is the major cause of obesity, affecting 13% of the worldwide adult

Nationwide Study in France To Predict One Year Major Bleeding and Validate the OAC3-PAD Score in Patients Undergoing Revascularisation for Lower Extremity Arterial Disease

European journal of vascular and endovascular surgery 2023 Aug;66(2):213-219.doi: 10.1016/j.ejvs.2023.04.026. Epub 2023 Apr 28. Fabien Lareyre, Christian-Alexander Behrendt, Christian Pradier, Nicla Settembre, Arindam Chaudhuri, Roxane Fabre, Juliette Raffort, Laurent Bailly Abstract Objective: Antithrombotic strategies are currently recommended for the treatment of lower extremity artery disease (LEAD)

Is Spinal Cord Stimulation Still Effective After One or More Surgical Revisions?

Neuromodulation 2023 Jul;26(5):1102-1108.doi: 10.1016/j.neurom.2023.03.009. Epub 2023 Apr 19. Aurelie Leplus, Jimmy Voirin, Emmanuel Cuny, Marie Onno, Maxime Billot, Philippe Rigoard, Denys Fontaine Abstract Objectives: Spinal cord stimulation (SCS) is burdened with surgical complications that may require one or several surgical revision(s), challenging its risk/benefit ratio and

The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2023 Sep;20(5):1305-1315.doi: 10.1007/s13311-023-01404-1. Epub 2023 Jul 12. Diane Merino, Alexandre O Gérard, Elise K Van Obberghen, Alexandre Destere, Michel Lanteri-Minet, Milou-Daniel Drici Abstract Migraine constitutes the world’s second-leading cause of disability. Triptans, as

Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care

Cephalalgia 2023 Jun;43(6):3331024231180611.doi: 10.1177/03331024231180611. Aubrey Manack Adams, Dawn C Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S Matharu, Zaza Katsarava, Michael L Reed, Kristina Fanning, Katherine Sommer, Richard B Lipton Abstract Background: The Chronic Migraine Epidemiology and Outcomes-International study provides insight into people with migraine in multiple countries. Methods:

Radiosurgery for classical trigeminal neuralgia: impact of the shot size on clinical outcome

The Journal of Headache and Pain 2023 May 11;24(1):51.doi: 10.1186/s10194-023-01583-4. Cécile Ortholan, Philippe Colin, Benjamin Serrano , Thibault Bouet, Nicolas Garnier, Maud le Guyader, Regis Amblard, Rémy Villeneuve, Stéphane Chanalet, Haiel Alchaar, Eric Bozzolo, Michel Lanteri-Minet, Denys Fontaine Abstract Background: This study compares the outcome of patients suffering from medically refractory classical

Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study

Cephalalgia 2023 May;43(5):3331024231170807.doi: 10.1177/03331024231170807. Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling, Patricia Pozo-Rosich Abstract Background: Migraine is a disabling neurological disease adversely affecting many aspects of life. Most patients are still required to have failed several older oral